Phase 1 / 2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer (AMEERA-1)

  • STATUS
    Recruiting
  • End date
    Aug 14, 2024
  • participants needed
    251
  • sponsor
    Sanofi
Send
Updated on 8 July 2022
See if I qualify
estrogen
measurable disease
endocrine therapy
hormone therapy
advanced breast cancer
HER2
erbb2
aromatase inhibitor
estrogen receptor
palbociclib
breast adenocarcinoma
exemestane

Summary

Primary Objectives:

Dose Escalation:

  • To assess the incidence rate of dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) as well as the recommended dose (RD) of amcenestrant administered as monotherapy and in combination with palbociclib
  • To assess the incidence rate of DLT and determine the RD of everolimus or abemaciclib in combination with the selected amcenestrant dose for the combination therapy

Safety Run-In:

  • To confirm the RD of amcenestrant in combination with alpelisib

Dose Expansion:

  • Antitumor activity using objective response rate (ORR)
  • Overall safety profile of amcenestrant administered in combination with palbociclib, alpelisib, everolimus, and abemaciclib

Secondary Objectives:

  • Overall safety profile of amcenestrant monotherapy and in combination
  • Pharmacokinetic (PK) profile of amcenestrant administered as monotherapy or in combination and PK profile of palbociclib, alpelisib, everolimus and abemaciclib
  • Antitumor activity using ORR, the clinical benefit rate (CBR) and progression free survival (PFS)
  • Time to first tumor response
  • Residual ER availability with positron emission tomography (PET) scan [(18)F] fluoroestradiol (18F-FES) uptake with increasing doses of amcenestrant
  • Food effect on PK of amcenestrant
  • Potential induction/inhibition effect of amcenestrant on cytochrome P450 (CYP) 3A using 4b-OH cholesterol

Description

Duration of the study, per participant, will include eligibility period (screening period) of up to 4 weeks (28 days), treatment period (at least 1 cycle [28 days] of study treatment), and end of treatment (EOT) visit at least 22 to 30 days (or until the participant receives another anticancer therapy, whichever is earlier) following the last study treatment administration. The expected enrollment period is approximately 60 months.

Details
Condition Breast Cancer
Treatment Everolimus, Palbociclib, Abemaciclib, Alpelisib, Amcenestrant
Clinical Study IdentifierNCT03284957
SponsorSanofi
Last Modified on8 July 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Participants must be postmenopausal women
Histological diagnosis of breast adenocarcinoma
Locally advanced or metastatic disease
Either primary tumor or any metastatic site to be positive for Estrogen Receptors (ER+) and negative for HER2 (HER2-) receptor
Participants must have been previously treated with at least 6 months of endocrine therapy for advanced disease
Dose Escalation study parts
Measurable lesion
Arm #3 - Part F and Arm #5 - Part J: up to 2 prior lines of either single endocrine therapy
and/or endocrine-based therapy Arm #4 -H: up to 2 prior lines of either single endocrine
therapy and/or endocrine-based therapy (exemestane not allowed)
Dose Expansion study parts: Arm #2: - Part D: no more than 2 prior lines of advanced
endocrine therapy for advanced disease are allowed Arm #3, - Part G: patients must have
received and progressed on the combination of Aromatase Inhibitors (AI) + CDK4/6 inhibitor
as the first line (1L) treatment for advanced disease Arm #4 - Part I: participants must
have received and progressed on the combination of Aromatase Inhibitors (AI) +CDK4/6
Inhibitor as the first line (1L) treatment for advanced disease (exemestane not allowed)
Arm#5: - Part K: up to 1 prior line of a single endocrine therapy for advanced disease
Note: Additional patients who relapsed while on previous adjuvant endocrine therapy that
was initiated ≥24 months ago, or relapsed < 12 months after completion of adjuvant
endocrine therapy are also allowed for Arms #2, #3, #4, and #5 (Parts C, D, F, G, H, I, J
and K)
Participants previously treated with chemotherapy for advanced disease: no more than 3
prior chemotherapeutic regimens in Arm #1 Part A, and no more than 1 prior
chemotherapeutic regimen in Arms #1, #2, #3, #4, and #5 (Parts B, C, D, F, H and J
respectively); prior chemotherapy for advanced disease is not allowed in dose
expansion of Arms #3, #4, and #5 (Part G, I and K respectively)

Exclusion Criteria

Participants with known brain metastases
Inadequate hematological and biochemical lab tests
Participants with Gilbert disease
Arm #3 (Parts F and G) only: ongoing osteonecrosis of jaw
Medical history or ongoing gastrointestinal disorders that could affect absorption of
oral study drugs (including difficulties with swallowing capsules)
The above information is not intended to contain all considerations relevant to a patient's
Participants with any other cancer (except for adequately treated basal cell or
potential participation in a clinical trial
squamous cell skin cancer, in situ cervical cancer or any other cancer from which the
participant has been disease free for >3 years)
Treatment with anticancer agents (including investigational drugs) less than 2 weeks
before first study treatment starts (less than 4 weeks if the anticancer agents were
antibodies)
Prior treatment with another selective ER down-regulator (SERD)
Dose Escalation study parts (Parts F, H and J): SERDs are not allowed except for
fulvestrant which will need a washout of at least 6 weeks prior to the first study
drug administration
Dose Expansion study parts (Parts G, I and K): prior (last) treatment with any SERD
including fulvestrant will not be allowed
Treatment with HIV-antiviral, antifungal and antioxidant agents less than 2 weeks
before study treatment starts
Treatment with strong P450 (CYP) 3A inducers within 2 weeks before first study
treatment
Treatment with OATP1B1/B3 sensitive substrates and which cannot be replaced
Arm#2 Treatment with strong CYP3A inhibitors within 2 weeks before first study
treatment starts
More than one prior advanced cyclin-dependent kinase (CDK) 4/6 inhibitor-based therapy
in Arm #1, Arm #2 (Part C), Arm #3 (Parts F and G), and Arm#4 (Part H)
Arm #2, #3, #4 and #5 (Parts C, D, F, G, H, I, J and K) only: participants with
concurrent or history of pneumonitis
Arm #3, #4 and #5 (Parts F, G, H, I, J and K) only: prior treatment therapies that
target the PI3K axis (mTOR inhibitors, AKT inhibitors, PI3K inhibitors)
Arm #3 and #4 (Parts F, G, H and I) only: participants with diabetes mellitus type-I
or uncontrolled diabetes mellitus type-II: ie, fasting plasma glucose ≥ 140mg/dl (7.7
mmol/l) or HbA1C > 6.2%
Arm #3 and #4 (Parts F, G, H and I) only: history of severe cutaneous reaction (eg
Stevens-Johnson syndrome [SJS], erythema multiforme [EM]), toxic epidermal necrolysis
(TEN), and drug reaction with eosinophilia and systemic symptoms [DRESS]
Arm #4 (Parts H and I) only: any active, untreated or uncontrolled infection (e.g
viral, bacterial, fungal etc.)
Arm #4 (Parts H and I) only: participants with active and uncontrolled stomatitis
angioedema due to concomitant treatment with ACE inhibitors, impaired wounds
Arm #4 (Parts H and I) only: uncontrolled hypercholesterolemia, hypertriglyceridemia
and hyperglycemia in non-diabetic participants
Arm #4 (Parts H and I) only: treatment with strong or moderate CYP3A4 inhibitors
strong CYP3A4 inducers and/or P-gp inhibitors within 2 weeks before the first study
treatment administration or 5 elimination half-lives, whichever is the longest
Arm #5 (Parts J and K) only: history or current (controlled/not controlled) venous
thromboembolism (i.e. deep vein thrombosis (DVT), pulmonary embolism (PE), cerebral
venous sinus thrombosis (CVST)
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

estrogen
measurable disease
endocrine therapy
hormone therapy
advanced breast cancer
HER2
erbb2
aromatase inhibitor
estrogen receptor
palbociclib
breast adenocarcinoma
exemestane

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note